EMD Millipore to acquire Biochrom

Thursday, August 23, 2012 09:54 AM

EMD Millipore, the life science division of Merck of Darmstadt, Germany, has decided to acquire Biochrom, a cell culture media specialist of Berlin, Germany. The closing price was not disclosed.

Biochrom employs 60 employees and had 2011 sales of approximately $16.3 million. The acquisition will strengthen EMD Millipore’s process solutions business unit, which provides products, services and solutions that simplify production complexity for pharmaceutical and biopharmaceutical manufacturers. Biochrom’s cell-culture media products are highly complementary, adding liquid cell-culture media and buffers including serum-free products and disposable packaging solutions to the existing portfolio.

 “With Biochrom we have a great opportunity to deliver an expanded portfolio of cell-culture media products to our global customers and address a growing demand for ready-to-use liquid solutions that drive safety and efficiency in the development and manufacture of clinical and commercial drug materials,” said Robert Yates, head of the EMD Millipore division.

Dr. Bernd Frenzel, CEO of Biochrom, added, “EMD Millipore is the ideal partner for Biochrom. With EMD Millipore we will be able to leverage their industry relationships and global footprint to reach more customers and offer a more comprehensive portfolio of media and buffers."

EMD Millipore will maintain Biochrom’s operations in Berlin. Closing of the transaction is expected in the fourth quarter of 2012.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs